PT795324E - Comprimido farmaceutico caracterizado por apresentar um elevado aumento volumerico quando colocado em contacto com fluidos biologicos - Google Patents

Comprimido farmaceutico caracterizado por apresentar um elevado aumento volumerico quando colocado em contacto com fluidos biologicos

Info

Publication number
PT795324E
PT795324E PT97102567T PT97102567T PT795324E PT 795324 E PT795324 E PT 795324E PT 97102567 T PT97102567 T PT 97102567T PT 97102567 T PT97102567 T PT 97102567T PT 795324 E PT795324 E PT 795324E
Authority
PT
Portugal
Prior art keywords
contact
volumeric
presenting
increase
biological fluids
Prior art date
Application number
PT97102567T
Other languages
English (en)
Portuguese (pt)
Inventor
Ubaldo Conte
Lauretta Maggi
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jagotec Ag filed Critical Jagotec Ag
Publication of PT795324E publication Critical patent/PT795324E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
PT97102567T 1996-02-19 1997-02-18 Comprimido farmaceutico caracterizado por apresentar um elevado aumento volumerico quando colocado em contacto com fluidos biologicos PT795324E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT96MI000311A IT1282650B1 (it) 1996-02-19 1996-02-19 Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici

Publications (1)

Publication Number Publication Date
PT795324E true PT795324E (pt) 2004-09-30

Family

ID=11373320

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97102567T PT795324E (pt) 1996-02-19 1997-02-18 Comprimido farmaceutico caracterizado por apresentar um elevado aumento volumerico quando colocado em contacto com fluidos biologicos

Country Status (12)

Country Link
US (1) US5780057A (instruction)
EP (2) EP1382331B1 (instruction)
JP (1) JP3251190B2 (instruction)
AT (2) ATE264670T1 (instruction)
AU (1) AU719170B2 (instruction)
CA (1) CA2197941C (instruction)
DE (1) DE69728710T2 (instruction)
DK (1) DK0795324T3 (instruction)
ES (2) ES2376199T3 (instruction)
IT (1) IT1282650B1 (instruction)
NZ (1) NZ314265A (instruction)
PT (1) PT795324E (instruction)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534263A (en) 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
US5804165A (en) * 1996-07-24 1998-09-08 Arnold; Michael J. Antiplaque oral composition
DE19640062B4 (de) * 1996-09-28 2006-04-27 Lts Lohmann Therapie-Systeme Ag Orale Zubereitung, enthaltend in einer in wässrigem Medium quellbaren Matrix wenigstens einen pharmazeutischen Wirkstoff
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
IT1294760B1 (it) * 1997-09-03 1999-04-12 Jagotec Ag Procedimento per la preparazione di compresse farmaceutiche in grado di cedere,secondo schemi predeterminabili, principi attivi poco
IN186245B (instruction) * 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
CA2287056C (en) * 1997-12-22 2000-08-15 Schering Corporation Orally administrable solid ribavirin dosage forms and process for making them
NZ508544A (en) * 1998-06-05 2002-10-25 Warner Lambert Co Angiotensin converting enzyme inhibitors, such as quinapril, enalapril and indolapril, stabilised with 1-90 wt% magnesium oxide
HK1039746A1 (zh) * 1998-09-25 2002-05-10 Delsys Pharmaceutical Corporation 用於口释放的液体药物
CA2354057C (en) 1998-12-11 2009-02-10 Nostrum Pharmaceuticals, Inc. Sustained release tablet containing hydrocolloid and cellulose ether
US6635281B2 (en) 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
MY121470A (en) * 1999-05-03 2006-01-28 Ranbaxy Lab Ltd Stable solid pharmaceutical compositions containing enalapril maleate
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
FR2797185B1 (fr) * 1999-08-06 2001-10-26 Galenix Dev Composition pharmaceutique flottante comprenant une phase active et une phase non active
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
JP4565456B2 (ja) * 1999-11-02 2010-10-20 塩野義製薬株式会社 着色顆粒の色素定着法
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
IL153497A0 (en) * 2000-06-23 2003-07-06 Teva Pharma Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
AU2002225763A1 (en) 2000-11-28 2002-06-11 Fmc Corporation Edible pga(propylene glycol alginate) coating composition
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
AU2002221412B2 (en) * 2000-12-05 2006-04-13 Alexander Macgregor Hydrostatic delivery system for controlled delivery of agent
KR100685945B1 (ko) 2000-12-29 2007-02-23 엘지.필립스 엘시디 주식회사 액정표시장치 및 그 제조방법
US8268333B2 (en) * 2001-04-24 2012-09-18 Lintec Corporation Orally administered agent and an orally administered agent/supporting substrate complex
DE10120092B4 (de) * 2001-04-25 2008-03-20 Lts Lohmann Therapie-Systeme Ag Magensaftresistente Vorrichtung zur Freisetzung von mukoadhäsiven Wirkstoffträgern und Verfahren zur Herstellung der magensaftresistenten Vorrichtung
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
IL159812A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
AU2002346372A1 (en) * 2001-11-13 2003-05-26 Teva Pharmaceutical Industries, Ltd. Process for the production of l-dopa ethyl ester
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
US6645526B2 (en) * 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
WO2003041646A2 (en) 2001-11-13 2003-05-22 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
ATE290387T1 (de) * 2001-12-21 2005-03-15 Biopartners Gmbh Ribavirin-granulat zur herstellung von filmtabletten
KR20030056474A (ko) * 2001-12-28 2003-07-04 한국유나이티드제약 주식회사 카르비도파/레보도파 서방정의 조성물과 그의 제조방법
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
CN1630513A (zh) * 2002-02-04 2005-06-22 兰贝克赛实验室有限公司 流体动力平衡的以两相释放的口服药物输递系统
US7008979B2 (en) * 2002-04-30 2006-03-07 Hydromer, Inc. Coating composition for multiple hydrophilic applications
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
SI1551372T1 (en) 2002-09-20 2018-08-31 Alpharma Pharmaceuticals Llc SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
KR20050083874A (ko) * 2002-10-31 2005-08-26 알자 코포레이션 액상 제제의 방출을 증진시키는 제형
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
JP2005132803A (ja) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd 胃内滞留固形剤
CA2550023C (en) 2003-12-16 2011-04-12 Cnsbio Pty Ltd Treatment of neuropathic pain
WO2005079752A2 (en) * 2004-02-11 2005-09-01 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
WO2005084703A1 (ja) * 2004-03-09 2005-09-15 Nrl Pharma, Inc. 徐放性の口腔用組成物
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
JP5046946B2 (ja) * 2004-10-15 2012-10-10 スパーナス ファーマシューティカルズ インコーポレイテッド 低乱用性薬学的製剤
CA2588418C (en) * 2004-11-19 2015-06-02 Smithkline Beecham Corporation Pharmaceutical product providing a plurality of components
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
JP2008525313A (ja) * 2004-12-27 2008-07-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗痴呆薬の安定化方法
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
EP1901720A2 (en) * 2005-06-23 2008-03-26 Spherics, Inc. Improved dosage forms for movement disorder treatment
JP2009500318A (ja) * 2005-06-29 2009-01-08 パナセア バイオテック リミテッド 新規な徐放性医薬組成物とその製法
ES2620293T3 (es) * 2005-09-09 2017-06-28 Paladin Labs Inc. Composición de liberación sostenida de fármacos
AU2006308449B8 (en) * 2005-09-09 2012-11-22 Angelini Labopharm, Llc Trazodone composition for once a day administration
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
EP1945189A4 (en) * 2005-11-03 2012-08-15 Sun Pharmaceutical Ind Ltd CONTROLLED RELEASE COATED TABLETS CHARACTERIZED BY PROLONGED GASTRIC RETENTION
WO2007056570A2 (en) * 2005-11-07 2007-05-18 Teva Pharmaceutical Industries Ltd. Levodopa compositions
US7674396B2 (en) * 2005-11-08 2010-03-09 Plensat Llc Method and system for treatment of eating disorders
US8691272B2 (en) 2005-12-30 2014-04-08 Intelgenx Corp. Multilayer tablet
KR100752417B1 (ko) * 2006-02-14 2007-08-28 대원제약주식회사 안정성이 증진된, 마진돌을 포함하는 약제학적 조성물
US9011930B2 (en) * 2006-05-01 2015-04-21 Zycal Bioceuticals Healthcare Company, Inc. Nutritional supplement and use thereof
EP2021005A4 (en) * 2006-05-03 2009-11-25 Cnsbio Pty Ltd METHOD AND COMPOSITION FOR THE TREATMENT OF INFLAMMATORY PAIN
WO2007138606A2 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
DK2484346T3 (en) 2006-06-19 2017-04-24 Alpharma Pharmaceuticals Llc Pharmaceutical compositions
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
KR101575679B1 (ko) * 2006-08-30 2015-12-08 자고텍 아게 코어 및 하나 이상의 배리어 층을 포함하는 방출 제어형 경구 투여 제제
WO2008039193A2 (en) * 2006-09-26 2008-04-03 Plensat, Llc Method and system for treatment of eating disorders
WO2008039186A2 (en) * 2006-09-26 2008-04-03 Plensat, Llc Method and system for treatment of eating disorders
JPWO2008041553A1 (ja) * 2006-09-26 2010-02-04 アステラス製薬株式会社 タクロリムス徐放性製剤
EP1935411A1 (en) 2006-12-15 2008-06-25 Campina Nederland Holding B.V. Slow release excipient and its use
AU2007338631A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
JPWO2008084698A1 (ja) 2006-12-28 2010-04-30 アステラス製薬株式会社 タクロリムス徐放性医薬組成物
AT505225A1 (de) 2007-04-26 2008-11-15 Sanochemia Pharmazeutika Ag 0erfahren zur herstellung von hoch reinem 2,4'-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
AU2009268934A1 (en) * 2008-06-16 2010-01-14 Appian Labs, Llc Composition and method of preparation of release systems for constant (zero-order) release of active agents
EP2326310B1 (en) 2008-08-15 2019-05-15 Assertio Therapeutics, Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders
US9622977B2 (en) * 2008-10-08 2017-04-18 Bioplus Life Sciences Pvt, Ltd. Sustained release drug delivery system
US20100112054A1 (en) * 2008-10-23 2010-05-06 Appian Labs, Llc Tablets and discs with compartments with two or more drugs for release at certain intervals and with specific rates
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
EP2210585A1 (en) 2009-01-16 2010-07-28 Exelgyn SPRM pharmaceutical compositions methods of treatment using them
US20100249423A1 (en) * 2009-03-09 2010-09-30 Sanochemia Pharmazeutika Ag Tolperisone controlled release tablet
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10485770B2 (en) 2009-12-21 2019-11-26 Aptapharma, Inc. Functionally-coated multilayer tablets
ES2665467T3 (es) 2010-03-29 2018-04-25 Astellas Pharma Inc. Composición farmacéutica de liberación modificada
JP5459670B2 (ja) * 2010-05-07 2014-04-02 塩野義製薬株式会社 着色顆粒の色素定着化剤
US20130143867A1 (en) * 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CA2862469A1 (en) 2012-01-23 2013-08-01 Ranbaxy Laboratories Limited In-situ multilayered tablet technology
EP3003297A4 (en) 2013-06-05 2017-04-19 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
WO2015054302A1 (en) 2013-10-07 2015-04-16 Impax Laboratories, Inc. Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10485758B2 (en) 2014-06-02 2019-11-26 Clexio Biosciences Ltd. Expandable gastroretentive dosage form
GB201506755D0 (en) 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
US10363288B2 (en) 2015-01-14 2019-07-30 National Jewish Health Insulin mimotopes and methods of using the same
CA2975676A1 (en) * 2015-02-09 2016-08-18 Entera Bio Ltd. Formulations for oral administration of active agents with controlled absorption profile
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
CA3018727C (en) 2016-03-24 2024-03-26 The Regents Of The University Of Colorado, A Body Corporate Methods of treating autoimmune disease
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
AU2017311698B2 (en) 2016-08-17 2024-09-05 Entera Bio Ltd. Formulations for oral administration of active agents
EP3547974B1 (en) 2016-12-02 2023-11-15 Clexio Biosciences Ltd. Gastric residence system
KR102039345B1 (ko) * 2017-02-01 2019-11-01 지엘팜텍주식회사 프레가발린 함유 고팽윤성 서방성 삼중정제
US11332438B2 (en) 2017-12-01 2022-05-17 Ultragenyx Pharmaceutical Inc. Creatine prodrugs, compositions and methods of use thereof
US11547839B2 (en) 2017-12-04 2023-01-10 Clexio Biosciences Ltd. Long acting gastric residence system
US11666546B2 (en) 2017-12-18 2023-06-06 Tris Pharma, Inc GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
WO2019126214A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
CN112004520B (zh) 2017-12-18 2024-08-23 特瑞斯制药公司 包括具有触发脉冲药物释放的胃内滞留筏形成系统的调节释放药物粉末组合物
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
JP7550393B2 (ja) * 2018-05-15 2024-09-13 ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド 低分子ｅｇｆｒ阻害剤を含む医薬組成物及びその製造方法
CN110214860A (zh) * 2019-07-10 2019-09-10 聂刘明 一种宠物饲料及其制备工艺
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
EP4267113A4 (en) 2020-12-22 2025-02-12 Amneal Pharmaceuticals LLC LEVODOPA DOSING SCHEME
JP2024528125A (ja) * 2021-07-30 2024-07-26 エヴェクシア セラピューティクス， インク． ５－ヒドロキシトリプトファン胃内滞留性剤形
US12409163B2 (en) 2021-07-30 2025-09-09 Evecxia Therapeutics, Inc. Method of enhancing 5-hydroxytryptophan (5-HTP) exposure
JP2024535585A (ja) 2021-10-14 2024-09-30 エヴェクシア セラピューティクス， インク． 脳内５－ヒドロキシトリプタミンの機能を治療目的で最適化する方法
WO2023214018A1 (en) 2022-05-06 2023-11-09 Galenix Innovations Gastro-retentive swellable sustained release composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4839171A (en) * 1984-11-30 1989-06-13 Techmix, Inc. Composition for treating impaired lactation
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
JPH0747534B2 (ja) * 1986-06-02 1995-05-24 ロ−ラ−ジヤパン株式会社 錠 剤
US4869908A (en) * 1987-01-09 1989-09-26 K.V. Pharmaceutical Co. Fibre formulations
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1256393B (it) * 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time

Also Published As

Publication number Publication date
ATE530173T1 (de) 2011-11-15
IT1282650B1 (it) 1998-03-31
JP3251190B2 (ja) 2002-01-28
NZ314265A (en) 1997-07-27
DK0795324T3 (da) 2004-08-16
EP0795324A3 (en) 1998-11-04
ITMI960311A0 (instruction) 1996-02-19
EP0795324A2 (en) 1997-09-17
CA2197941C (en) 2001-12-04
DE69728710D1 (de) 2004-05-27
ES2376199T8 (es) 2012-04-04
DE69728710T2 (de) 2005-04-07
ATE264670T1 (de) 2004-05-15
US5780057A (en) 1998-07-14
EP1382331B1 (en) 2011-10-26
EP1382331A1 (en) 2004-01-21
EP0795324B1 (en) 2004-04-21
JPH09316005A (ja) 1997-12-09
ITMI960311A1 (it) 1997-08-19
AU719170B2 (en) 2000-05-04
AU1477697A (en) 1997-08-28
CA2197941A1 (en) 1997-08-20
ES2376199T3 (es) 2012-03-09
ES2219709T3 (es) 2004-12-01

Similar Documents

Publication Publication Date Title
PT795324E (pt) Comprimido farmaceutico caracterizado por apresentar um elevado aumento volumerico quando colocado em contacto com fluidos biologicos
ATE205705T1 (de) Arzneimittel zum wirkstoff - targetting in den dickdarm
AU7534087A (en) Sustained release pharmaceutical compositions in oral dosage form
KR880002502A (ko) 산에 민감한 유익한 약제의 투여용 제형(劑形)
WO2001037812A3 (en) Gastroretentive controlled release pharmaceutical dosage forms
MX9604354A (es) Nueva forma de dosis farmaceutica oral.
DK0841903T3 (da) Orale farmaceutiske præparater indeholdende antimikrobielt virksomme aktivstoffer og sustained release pantoprazol
CA2264250A1 (en) Tablet with controlled release of alfuzosin hydrochloride
EP1243267A3 (en) Amoxycillin and clavulanate containing pharmaceutical formulation
ATE173159T1 (de) Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
ATE264666T1 (de) Im magen verweilendes arzneimittel mit verzögerter wirkstoffabgabe
AU681452B2 (en) Pernasal composition and pernasal preparation containing thesame
ES2088956T3 (es) Estructura de tableta multifraccionable.
NO992944L (no) Virkestoffbµrer for avgivelse av apomorfin i munnhulen
ATE124255T1 (de) Im dickdarm zerfallende, polypeptide enthaltende orale formulierungen.
HRP20010684B1 (hr) Izravno stlaciva matrica za kontrolirano otpustanje jednostruke dnevne doze klaritromicina
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
ES2149341T3 (es) Expulsion de un material a partir de un dispositivo de liberacion.
DE69831940D1 (de) Tablette mit verlängerter Wirkstoffabgabe im Magen
KR950013513A (ko) 약제 제조용 모에노마이신 및 이의 유도체, 및 모에노마이신 또는 이의 유도체를 함유하는 약제
AR022621A1 (es) Composicion farmaceutica que contiene desoxipeganina para el tratamiento de la dependencia de la nicotina
KR920019365A (ko) 디리트로마이신을 함유하는 약학 제형
JP2001316293A5 (instruction)
Elperin et al. A patient's guide to protease inhibitors
EP0761209A3 (en) Controlled release formulations of ranitidine